- Trials with a EudraCT protocol (190)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (3)
190 result(s) found for: Venous Thromboembolism.
Displaying page 7 of 10.
EudraCT Number: 2005-004486-42 | Sponsor Protocol Number: CaVenT | Start Date*: 2006-01-03 |
Sponsor Name:Eastern Norway Regional Health Authority [...] | ||
Full Title: Catheter-directed Venous Thrombolysis (CaVenT) in Acute Iliofemoral Vein Thrombosis - an open Randomized, Controlled, Clinical Trial | ||
Medical condition: Acute ilio-femoral vein thrombosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-017313-30 | Sponsor Protocol Number: BAY59-7939/12892 | Start Date*: 2010-06-04 |
Sponsor Name:Bayer HealthCare AG | ||
Full Title: Single-dose pilot study of oral rivaroxaban in pediatric subjects with venous thromboembolism | ||
Medical condition: Venous thromboembolism. | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: AT (Completed) DE (Completed) IT (Completed) IE (Completed) FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-005090-20 | Sponsor Protocol Number: FADOI.01.2016 | Start Date*: 2018-05-17 | ||||||||||||||||
Sponsor Name:FONDAZIONE FADOI | ||||||||||||||||||
Full Title: Rivaroxaban or placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer: a randomized, double blind, placebo-controlled study. THE PRO-LAPS STUDY II | ||||||||||||||||||
Medical condition: Prevention of venous thromboembolism after laparoscopic surgery for colorectal cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003342-25 | Sponsor Protocol Number: P170604J | Start Date*: 2018-09-07 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Long-term treatment of cancer associated VTE Optimal dose of apixaban API-CAT STUDY for APIxaban Cancer Associated Thrombosis | |||||||||||||
Medical condition: Patients with breast, prostate, and colorectal active cancer, with objectively documented index event of symptomatic or incidental proximal DVT or symptomatic or incidental PE, after 6 months of an... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) PL (Ongoing) ES (Restarted) GB (GB - no longer in EU/EEA) BE (Completed) GR (Completed) AT (Ongoing) NL (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003076-14 | Sponsor Protocol Number: ANT-007 | Start Date*: 2022-05-10 |
Sponsor Name:Anthos Therapeutics | ||
Full Title: A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in ... | ||
Medical condition: venous thromboembolism (VTE) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: LV (Trial now transitioned) NO (Trial now transitioned) FR (Trial now transitioned) IE (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) IT (Trial now transitioned) HU (Trial now transitioned) SE (Trial now transitioned) AT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003085-12 | Sponsor Protocol Number: ANT-008 | Start Date*: 2022-05-10 |
Sponsor Name:Anthos Therapeutics | ||
Full Title: A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding i... | ||
Medical condition: venous thromboembolism (VTE) in patients with gastrointestinal/genitourinary cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: LV (Trial now transitioned) NO (Trial now transitioned) FR (Trial now transitioned) IE (Trial now transitioned) ES (Ongoing) HU (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) SE (Trial now transitioned) AT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2015-002668-18 | Sponsor Protocol Number: TiMM | Start Date*: 2015-12-29 | ||||||||||||||||
Sponsor Name:King’s College Hospital NHS Foundation Trust | ||||||||||||||||||
Full Title: The role of apixaban, aspirin and enoxaparin as Thromboprophylaxis in patients newly diagnosed with Multiple Myeloma - an open label randomised control clinical trial | ||||||||||||||||||
Medical condition: Multiple myeloma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-002562-40 | Sponsor Protocol Number: 16-021 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Portola Pharma UK Ltd | |||||||||||||
Full Title: A phase 1, open-label, single dose, non-randomized study to evaluate pharmacokinetics, pharmacodynamics, and safety of Betrixaban in pediatric patients. | |||||||||||||
Medical condition: Pediatric patients who are assessed to be at risk for Venous thromboembolism (VTE) but does not require immediate anticoagulant therapy, for example: a. Has previous thrombosis and completed a cour... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014290-40 | Sponsor Protocol Number: DU176b-D-U305 | Start Date*: 2010-02-10 | ||||||||||||||||
Sponsor Name:Daiichi Sankyo Development Limited | ||||||||||||||||||
Full Title: A phase 3, randomized, double-blind, double-dummy, parallel-group, multi-center, multi-national study for the evaluation of efficacy and safety of (LMW) heparin/edoxaban versus (LMW) heparin/warfar... | ||||||||||||||||||
Medical condition: Reduction of the risk of symptomatic recurrent venous thromboembolic complications in patients with acute symptomatic deep vein thrombosis (DVT) and/or pulmonary embolism (PE) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) HU (Completed) DE (Completed) SE (Completed) FR (Completed) EE (Completed) BE (Completed) AT (Completed) ES (Completed) DK (Completed) CZ (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-005022-18 | Sponsor Protocol Number: PACeS | Start Date*: 2022-07-26 | |||||||||||
Sponsor Name:Icahn School of Medicine at Mount Sinai | |||||||||||||
Full Title: Anticoagulation for New-Onset Post-Operative Atrial Fibrillation after CABG | |||||||||||||
Medical condition: New-Onset Post-Operative Atrial Fibrillation after CABG | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002631-86 | Sponsor Protocol Number: 1160.46 | Start Date*: 2008-10-23 | ||||||||||||||||
Sponsor Name:Boehringer Ingelheim Austia Gm.b.H | ||||||||||||||||||
Full Title: A phase III, randomised, double blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute sy... | ||||||||||||||||||
Medical condition: Acute symptomatic VTE VTE is defined as the composite incidence of Deep Vein Thrombosis of the leg (including the inferior caval vein) and Pulmonary Embolism. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BG (Completed) SK (Completed) ES (Completed) GB (Completed) NL (Completed) DK (Completed) CZ (Completed) SE (Completed) HU (Completed) FR (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-002402-60 | Sponsor Protocol Number: BAY 59-7939/11355 | Start Date*: 2007-03-27 | |||||||||||
Sponsor Name:Bayer Pharmaceutical | |||||||||||||
Full Title: RECORD 4 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE; a controlled, double-blind, randomized study of BAY 59-7939 in the prevention of VTE in subjects undergoing el... | |||||||||||||
Medical condition: Prevention of venous thromboembolism | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) SE (Completed) DK (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-006056-37 | Sponsor Protocol Number: 1160.143 | Start Date*: 2013-09-05 | |||||||||||
Sponsor Name:Hamilton Health Sciences Corporation | |||||||||||||
Full Title: A large, international, randomized, placebo-controlled trial to assess the impact of dabigatran (a direct thrombin inhibitor) and omeprazole (a proton-pump inhibitor) in patients suffering myocardi... | |||||||||||||
Medical condition: MINS (myocardial injury after noncardiac surgery) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) IT (Completed) PT (Completed) ES (Completed) GB (Completed) AT (Completed) DE (Prematurely Ended) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001534-11 | Sponsor Protocol Number: GIT-PRo-2022-02 | Start Date*: 2022-10-11 | ||||||||||||||||
Sponsor Name:Grupo Gallego de Investigación en Tumores Digestivos (GITuD) | ||||||||||||||||||
Full Title: Prophylaxis of venous thromboembolic disease with LMWH (TINzaparin) in patients with metastatic colorectal cancer who start the first line of treatment. | ||||||||||||||||||
Medical condition: Metastatic colorectal cancer (mCRC), stage IV that initiates the first-line systemic treatment in the metastatic setting | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004691-20 | Sponsor Protocol Number: BAY 59-7939/11357 | Start Date*: 2006-01-09 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: RECORD 2 Study: REgulation of Coagulation in ORthopedic Surgery to prevent DVT and PE, controlled, Double-Blind, Randomized Study of BAY59-7939 in the Extended Prevention of VTE in Patients Undergo... | |||||||||||||
Medical condition: Prevention of venous thromboembolism | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SE (Completed) LT (Completed) DK (Completed) EE (Completed) PT (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004550-15 | Sponsor Protocol Number: 64179375THR2001 | Start Date*: 2017-10-11 |
Sponsor Name:Janssen-Cilag International NV | ||
Full Title: A Randomized, Double-blind, Double-dummy, Multicenter, Adaptive Design Dose-Escalation (Part 1) and Dose-Response (Part 2) Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Vers... | ||
Medical condition: Thromboembolism in subjects who have undergone an elective primary unilateral total knee replacement | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) ES (Completed) PL (Completed) LV (Completed) LT (Prematurely Ended) BG (Completed) GR (Completed) PT (Completed) IT (Completed) RO (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2005-004620-40 | Sponsor Protocol Number: BAY 59-7939/11356 | Start Date*: 2006-01-26 | |||||||||||
Sponsor Name:Bayer HealthCare AS | |||||||||||||
Full Title: RECORD 3 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE; controlled, double-blind, randomized study of BAY 59-7939 in the prevention of VTE in subjects undergoing elec... | |||||||||||||
Medical condition: Prevention of venous thromboembolism | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) SE (Completed) DE (Completed) DK (Completed) BE (Completed) ES (Completed) CZ (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002345-38 | Sponsor Protocol Number: 12/0033/CTU/IMM/001 | Start Date*: 2012-10-30 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: A prospective randomised controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE. | |||||||||||||
Medical condition: Patients with antiphospholipid syndrome (APS), with or without systemic lupus erythematosus (SLE). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004450-24 | Sponsor Protocol Number: PHIX-IT | Start Date*: 2019-08-01 |
Sponsor Name:Tergooi Hospital, dep of internal medicine | ||
Full Title: A pharmacokinetic study of edoxaban in patients with breast cancer using the P-glycoprotein inhibitor tamoxifen | ||
Medical condition: If there are increased plasma levels of edoxaban when used concomitantly with the P-glycoproteïne inhibitor tamoxifen for the treatment of venous thromboembolism in patients with breast cancer. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001841-38 | Sponsor Protocol Number: Col-VID | Start Date*: 2020-05-25 |
Sponsor Name:Sociedad Española de Cardiología | ||
Full Title: Colchicine for the Treatment of Hyperinflammation associated with Pneumonia due to COVID-19 | ||
Medical condition: Hyperinflammation associated with Pneumonia due to COVID19 | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
